August 2012
-
In the wake of the EMA’s recent recommendation against use the use of calcitonin nasal sprays due to an increased risk of cancer, Health Canada says that it is also evaluating the risks of calcitonin… Read more . . .
-
The FDA has approved Watson Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for a generic version of Pulmicort Respules. The budesonide inhalation suspension 0.25mg/2mL and 0.5mg/2mL ampules are the subject of an ongoing patent dispute with… Read more . . .
-
According to a report in The Business Standard, Novartis India has announced an agreement with Lupin to sell the Onbrez indacaterol inhalation capsules for the treatment of COPD in India. The newspaper cited “an industry… Read more . . .
-
A temporary position is available in the FDA laboratory in Saint Louis, MO to develop a more efficient method for evaluating aerodynamic particle size distribution for dry powder inhalers (DPIs). Also to evaluate various abbreviated… Read more . . .
-
According to Sunovion Pharmaceuticals, Zetonna ciclesonide nasal aerosol for the treatment of perennial and seasonal allergic rhinitis is now available throughout the US. The company announced in May that it would launch the product by… Read more . . .
-
Quintiles will promote respiratory drugs from Almirall in the UK, starting with the newly approved Eklira Genuair aclidinium bromide dry powder inhaler for the treatment of COPD. Quintiles performed some of the clinical study work… Read more . . .
-
Health Canada has issued an advisory to health care professionals that “AstraZeneca Canada has received a small number of product complaints for Pulmicort Turbuhaler, 200 µg per metered dose (200 doses) regarding the malfunction of… Read more . . .
-
Unigene Laboratories, which manufactures Fortical calcitonin nasal spray for the treatment of osteoporosis, has requested product safety data submitted to the EMA’s Committee for Medicinal Products for Human Use (CHMP) in response to the EMA’s… Read more . . .
-
The UK Department of Health has announced that Health Secretary Andrew Lansley has agreed to a flu vaccination program recommended by a committee of independent experts that will provide MedImmune’s Fluenz intranasal vaccine to all… Read more . . .
-
Just after announcing the approval of the Tudorza Pressair aclidinium bromide dry powder inhaler for the treatment of COPD in the US, Almirall has announced that the European Commission has granted marketing approval to its… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland